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Background: Recent reports suggest an increase in use of extremely potent cannabis 
concentrates such as Butane Hash Oil (BHO) in some developed countries. The aims of this 
study were to examine the characteristics of BHO users and the effect profiles of BHO.  
Design: Anonymous online survey in over 20 countries in 2014 and 2015. Participants aged 18 
years or older were recruited through onward promotion and online social networks. The overall 
sample size was 181,870. In this sample, 46% (N = 83,867) reported using some form of 
cannabis in the past year, and 3% reported BHO use (n = 5,922). 
Measurements: Participants reported their use of 7 types of cannabis in the past 12 months, the 
source of their cannabis, reasons for use, use of other illegal substances, and lifetime diagnosis 
for depression, anxiety and psychosis. Participants were asked to rate subjective effects of BHO 
and high potency herbal cannabis. 
Findings: Participants who reported a lifetime diagnosis of depression (OR = 1.15, p = .003), 
anxiety (OR = 1.72, p < .001) a larger number of substance use (OR = 1.29, p < .001) were more 
likely to use BHO than only using high potency herbal cannabis. BHO users also reported 
stronger negative effects and less positive effects when using BHO than high potency herbal 
cannabis (p < .001)  
Conclusion: Mental health problems and other illicit drug use were associated with use of BHO. 
BHO was reported to have stronger negative and weaker positive effects than high potency 
herbal cannabis. 
KEY WORDS: [cannabis concentrate, potency, butane hash oil, THC, user characteristics, 
profile] 
1 Introduction 
Cannabis is the most widely used illicit substance globally and this is particularly the case 
in developed countries. For example, the prevalence of past year cannabis use is 13%, 10% and 
12% in the US (SAMHSA, 2014), Australia (AIHW, 2014) and Canada (Rotermann & Langlois, 
2015) respectively. There is also evidence that cannabis use has spread to low- and middle-
income countries, with a reported prevalence of 7.5% in African countries (UN Office on Drugs 
and Crime, 2015).   
Cannabis users often report relaxation, euphoria, increased sociability and sexual pleasure 
as the main positive effects (Green et al., 2003). These effects are largely attributable to delta-9-
tetrahydrocannabinol (THC), the primary psychoactive constituent in cannabis, but they may 
also be modulated by cannabidiol (CBD) (Curran et al., 2016; Englund et al., 2017; Iversen, 
2001). Cannabis potency is usually defined by THC content, which varies by preparation type 
(for example, resin, oil or herbal), strain of cannabis and method of cultivation. In 2008,  the 
domestic UK market was dominated by high potency, indoor-grown varieties (e.g. skunk, 
sensimilla) which contain the highest THC content (approximately 15%), followed by outdoor-
grown herbal cannabis (9%) and hash/resin (5%) (Hardwick & King, 2008). Similar results were 
found for cannabis obtained from UK cannabis users in a naturalistic setting (Freeman et al., 
2014), but recent monitoring data are lacking (Freeman & Swift, 2016). In the Netherlands, 
popular indoor grown herbal cannabis increased in THC content from 9% in 2000 to 20% in 
2004 (Pijlman et al., 2005) before decreasing to 15% in 2015 (Niesink et al., 2015). Data from 
drug enforcement agency seizures (ElSohly et al., 2016) indicated high potency herbal cannabis 
has become increasingly prevalent in the USA with the overall potency of illicit cannabis rising 
from 4% in 1995 to 12% in 2014. Based on the results of a single study, the Australian cannabis 
market is similarly dominated by high potency herbal cannabis containing approximately 15% 
THC (Swift et al., 2013). There is some evidence that use of high potency herbal cannabis (e.g. 
skunk, sensimilla) is associated with greater harms (Hall & Degenhardt, 2015), including higher 
levels of dependence (Freeman & Winstock, 2015) and an increased risk of developing a 
psychosis (Di Forti et al., 2015).  
More efficient methods of hash/resin production have also been used to produce higher 
potency products (e.g. 30-40% THC in the United States and Netherlands) (ElSohly et al., 2016; 
Niesink et al., 2015). Recently, new refined cannabis products with unprecedentedly high THC 
content (cannabis concentrates) have received increased media coverage in the US (Cavazos-
Rehg et al., 2016; Daniulaityte et al., 2015; Stogner & Miller, 2015a, 2015b). Their production 
appears to have been driven by growth in the medicinal cannabis industry in the US, with the 
intention of allowing users to limit their exposure to smoked herbal products by using smaller 
doses of more potent cannabis extracts. Butane Hash Oil (BHO) is one example, commonly 
referred to as “earwax”, “dabs”, “butter” and “shatter”. It can be prepared through a process 
called blasting, which involves passing butane through a steel or glass tube packed with dried 
cannabis trimmings to dissolve the THC. The butane-THC solution is then filtered and BHO 
obtained by evaporating the butane (Stogner & Miller, 2015b). Alternative methods of extraction 
include different solvents (e.g. propane) or carbon dioxide extraction. These new methods can 
produce “cannabis concentrates” with THC content as high as 76% (Raber et al., 2015). The 
maximum THC content achievable using these new extraction techniques exceeds more 
traditional methods (e.g. dry extraction to ‘kief’, water extraction to ‘bubble hash’) (Raber et al., 
2015) and is considerably stronger than high potency herbal cannabis (e.g. 15%). Cannabis 
concentrate users often obtain a very high dosage of THC in a single hit through a process 
known as “dabbing”, in which they heat up the product with a blow torch and inhale the vapor 
via a bong or oil pipe. With e-cigarettes becoming more popular and accessible, a small but 
significant number of young people report using e-cigarettes to vaporize liquid hash oil (Morean 
et al., 2015). Additional concerns are that the solvent-based extraction methods (e.g. BHO) pose 
a significant risk of explosion and associated injury or death during production (Crawford, 2016; 
Jensen, Bertelotti, et al., 2015). They also leave residual solvents in the final product (Raber et 
al., 2015). These concerns may be offset by using different extraction methods (e.g. carbon 
dioxide), but the prevalence of use of these respective methods is currently unclear. 
The high THC content in cannabis concentrates and the rapid ingestion of THC might be 
associated with higher level of dependence, stronger withdrawal and the swifter development of 
tolerance (Loflin & Earleywine, 2014). While the long term effects of cannabis concentrates 
such as BHO use are largely unknown, a recent study suggests that their use may heighten short 
term harms and produce more extreme acute effects, such as fainting (Miller et al., 2016). Use of 
concentrates has also been associated with an increased incidence of orthostatic hypotension 
leading to falls and injuries and emergency department visits for burns from explosions caused 
by overheated elements in “vape pens” (Russo, 2016).  
There are other health risks associated with concentrates. A recent study found that up to 
70% of pesticide residues may be recruited into the smoked product (Sullivan et al., 2013) even 
in concentrates produced industrially for markets in US states where use is legal (Russo, 2016). 
Along with the increased popularity of e-cigarettes and vaping devices, there is an emerging 
trend for young people to use these devices to vaporise cannabis concentrate (Morean et al., 
2015). This might add extra health risk because data from e-cigarette research has shown that the 
solvents propylene glycol and glycerine, when overheated can produce formaldehyde, a known 
carcinogen (Jensen, Luo, et al., 2015). This finding has been confirmed in studies of thinning 
agents used by cannabis oil commercial producers in Colorado (Troutt & DiDonato, 2017). 
Users also described a qualitative difference between the effects of BHO and traditional herbal 
cannabis, with the high produced from BHO more like that achieved by using “harder” drugs 
(Miller et al., 2016). Despite public health concerns about the recent popularity of BHO and 
other high potency extracts, there is limited research on their effects. To date the few published 
studies have been limited by small sample sizes, and these have not yet adequately characterized 
users. The aims of this study were to examine the profile and characteristics of BHO users, and 
to compare the effect profiles of BHO and high potency herbal cannabis in a very large sample 
of drug users recruited in the Global Drug Survey (GDS) in 2015 and 2016. 
2 Methods 
2.1 Sample 
GDS is the largest annual survey of drug use in the world. It uses anonymous, encrypted 
online survey methods to provide rapid access to very large numbers of sentinel drug-using 
populations (Winstock et al., 2015). As such it is a useful tool for identifying new trends in drug 
use, drug-related harms and routes of administration (Barratt et al., 2017; Hindocha et al., 2016; 
Winstock et al., 2011). Data from GDS 2015 and GDS 2016 were used for this study. The 
overall sample size after data cleaning was 181,870. Sixty three percent of the participants were 
males and the mean age was 29.01 (SD = 11.38; Median: 25). Among this sample, 46% (n = 
83,867) reported using some form of cannabis in the past year, and 3% reported BHO use (n = 
5,922). 
2.2 Procedure 
GDS 2015 and GDS 2016 were launched in November 2014 and 2015 respectively 
through global media partners. Participants were recruited through onward promotion and online 
social networks on websites including The Guardian, Vice, Ziet-on-Line, Liberation, Fairfax 
Media in Australia and New Zealand and other international publications. The survey was 
translated into 10 languages and has partners in over 20 countries. All participants confirmed that 
they were aged ≥16 years, and consented for the information they gave to be analysed. Ethical 
approval was received from the joint South London and Maudsley and Institute of Psychiatry, 
Psychology and Neuroscience National Health Service (NHS) Research Ethics Committee.  
2.3 Measures 
Cannabis use. Participants were shown pictures of seven forms of cannabis products, 
including indoor grown high potency herbal cannabis, resin/ hash, outdoor grown herbal weed/ 
bush/ pressed, edible cannabis, kief, oil and BHO. Self-reported measures of cannabis type have 
previously been validated against objective THC and CBD content (Freeman et al., 2014; van der 
Pol et al., 2013). Pictorial aids were used to improve their acceptability among an international 
sample with diverse cannabis terminology (Potter & Chatwin, 2012). Participants were asked to 
indicate which types of cannabis they had used in the last 12 months, and were then assigned to 
four cannabis user groups, 1) Non-user (NON), 2) Cannabis user – No high potency herbal 
cannabis and BHO use (CANN), 3) High potency herbal cannabis users with no BHO use (HI-
POT), and 4) BHO users. These categories were mutually exclusive. Table 1 shows the types of 
cannabis used by the four groups. For participants who classified as CANN, 95% used normal 
weed and none used high potency herbal cannabis or BHO; for participants who were HI-POT, 
all of them used high potency herbal cannabis but no BHO use; BHO users tended to use a wide 
range of cannabis products. 
Source of cannabis was assessed using the items “How do you acquire your cannabis?” 
with the following response items: “I buy it”, “I grow it” and “I get it on prescription”. These 
responses were not mutually exclusive. For reasons of use, participants were asked to choose one 
of the following reasons “I use cannabis exclusively for recreational (pleasure) purposes”, “I use 
cannabis sometimes for medical reasons and most of the time for recreational purposes”, “I use 
cannabis most of the time for medical reasons and sometimes for recreational purposes” and “I 
use cannabis exclusively for medical reasons”. The subjective effects of BHO and high potency 
herbal cannabis were measured using 20 items on a 10-point scale (From 1 “Least” to 10 
“Maximum”). Example items were “How strong would you rate this type of cannabis overall?” 
and “How would you rate its overall pleasurable effects?” Only data from participants who 
reported both BHO and high potency herbal cannabis use were included in the comparison of 
subjective effects. 
Other drug use. Participants were given a list of drugs, including MDMA, Cocaine, 
Amphetamine/ Methamphetamine, Heroin and LSD, and were asked to indicate if they had used 
each of them in the past 12 months. Mental Health. Participants were asked to indicate if they 
had received a diagnosis for depression, anxiety and/or psychosis in their lifetime. 
2.4 Analysis 
Comparisons of types of cannabis users and their demographic variables, mental health 
variables, other substance use variables, source of cannabis and reasons for use were performed 
using chi-square tests and ANOVAs. Two multinomial logistic regressions examined the 
adjusted associations between these variables and group membership. The reference groups in 
these two models were CANN and HI-POT respectively. Missing data were accounted for by 
multiple imputation. Five datasets were imputed to fill in missing values in the data (Rubin, 
2009). Paired-sample t-tests were used to compare the subjective effects of high potency herbal 
cannabis and BHO in those participants who reported use of both types of cannabis. All analyses 
were done in STATA 13 (StataCorp, 2013). 
3 Results 
Table 2 shows the demographic profiles of different types of cannabis users. BHO users 
were younger, more likely to be male, less likely to have attained a higher education, less likely 
to be heterosexual, and more likely to use cannabis daily/almost daily, than non-users and 
cannabis users who had not used high potency cannabis use or BHO (p < .001).  
Tables 3 shows the substance use, mental health and reason for use profiles of BHO 
users. They were more likely to use MDMA, cocaine, amphetamine/methamphetamine, heroin 
and LSD (p < .001) and were more likely to report a lifetime diagnosis of psychosis, depression 
and anxiety (p < .001). BHO users were more likely to have obtained their cannabis through 
prescription and to report using cannabis for medical purposes. Both high potency herbal 
cannabis users and BHO users were also more likely to report growing and purchasing their 
cannabis.  
Table 4 shows the results from multinomial logistic regressions. Compared to CANN, 
participants who were male, OR = 3.07, p < .001, transgender, OR = 2.14, p < 001, bisexual, OR 
= 1.19, p < .001, had lifetime diagnosis for depression, OR = 1.34, p < .001 and anxiety, OR = 
1.80, p < .001, and used a large number of substances, OR = 1.66, p < .001 were more likely to 
be BHO users. Having a higher level of education (p < .001) and being younger, OR = 0.99, p < 
.001 were associated with a lower likelihood of BHO use.  
Compared to HI-POT users (Last 2 columns in Table 4), participants who were older, OR 
= 1.01, p < .001, male, OR = 1.48, p < .001, bisexual, OR = 1.22, p < .001, had lifetime 
diagnosis of depression, OR = 1.15, p = .003 and anxiety, OR = 1.72, p < .001, and used a larger 
number of illicit substances, OR = 1.29, p < .001, were more likely to be BHO users. Having a 
higher level of education was associated with a lower likelihood of BHO use, p < .001.  
Table 5 shows the effect profiles of BHO and high potency herbal cannabis. Users of 
both types of cannabis generally reported that BHO was stronger than high potency herbal 
cannabis and they reported more negative and fewer positive effects when they used BHO. 
4 Discussion 
In the largest study to date, we found that BHO use was strongly associated with higher 
rates of self-reported anxiety and depression and other illicit drug use than high-potency herbal 
cannabis. BHO users were more likely to have a lower education level and to be bisexual. These 
results were generally consistent with previous research showing that users of more potent form 
of cannabis (higher level of THC) experienced higher level of harms, such as a stronger 
association between high potency cannabis and psychosis (Di Forti et al., 2015), and higher 
levels of cannabis dependence (Freeman & Winstock, 2015).  
We found a significant association between cannabis potency and mental health profiles. 
Participants with a lifetime diagnosis of depression were 1.18 more likely to use high-potency 
herbal cannabis and 1.34 more likely to use BHO. A similar pattern was found for anxiety. 
Although participants with a diagnosis of anxiety were no more likely to use high potency herbal 
cannabis, they were 1.80 times more likely to use BHO.  BHO use was not associated with 
lifetime diagnosis of psychosis but this non-significant result should be interpreted with caution 
because the rate of psychosis in the sample was very low. Consistent with previous research (Di 
Forti et al., 2015), use of high-potency herbal cannabis was associated with a greater incidence of 
psychosis than use of less potent forms of cannabis and no cannabis use. 
Our study was cross-sectional and so causality cannot be inferred. It is possible that 
participants with a worse mental health profile may use BHO to self-medicate symptoms of 
depression and anxiety (Hall & Degenhardt, 2015). Our finding that BHO users were much more 
likely to report using cannabis for medical purposes and to obtain their cannabis via prescription 
was consistent with this self-medication hypothesis. However, the relationship between BHO use 
and poorer mental health may also be bidirectional. While using cannabis with high THC content 
may improve mood in the short term, it could exacerbate users’ symptom in long term (Hall & 
Degenhardt, 2015). It may also be that people who use cannabis to treat medical conditions are 
themselves more likely to report poorer mental health, given the association between chronic 
physical illness and poorer mental health (De Hert et al., 2011). Further research is needed to 
determine the incidence of adverse effects of BHO for medical use.  
A previous qualitative study found that BHO users were enthusiastic about its effects 
which they reported as positive and pleasurable (Miller et al., 2016). However, that study was 
limited by a small sample size (n=6) and only included people involved in treatment for drug-
involved offences. By contrast, our large global dataset on participants who had experience with 
both BHO and high potency herbal cannabis showed that the effect profiles of BHO and high 
potency herbal were similar but BHO users generally reported more negative experiences, such 
as being more restless and anxious, and more forgetful when stoned. They also reported fewer 
positive experiences with BHO, such as feeling less pleasure and less relaxed. Interestingly, the 
largest difference we found was a lower ‘urge to use more when stoned’ for BHO than for high 
potency herbal cannabis. This finding is consistent with human and animal data suggesting that 
extremely high doses of THC are less reinforcing (and can be more aversive) than moderately 
high doses (Curran et al., 2016).  
There are several limitations in the current study. Firstly, our sample is a non-probability 
sample. However, the web-based method used in the GDS was an efficient way of gaining in-
depth knowledge of drug use behaviours, and this is best suited to the comparison of use patterns 
and harms between population sub-segments. While this method allowed us to recruit a large 
sample who reported BHO use, this might limit the generalizability of our findings to the general 
population. However, it should be noted that prevalence of BHO use in the general population 
was low, and the cost of undertaking a general population survey to obtain a comparable sized 
sample would be prohibitively high. Our sample was from a sentinel drug-using population and 
provided important information about the characteristics of BHO users. Second, our study was 
based on cross-sectional self-reported survey, and therefore, causality cannot be inferred. In 
common with most online surveys, we were not able to assess the mental condition of the 
participants at the time of the survey, and we were not able to check if the participants gave 
consent under the influence of any substance. However, since the survey is completely 
anonymous and participants can withdraw from the study anytime by closing their web browser, 
there would be minimal risks to the participants. Thirdly, we focused on a single extraction 
technique (butane) and did not address alternative methods such as carbon dioxide (Raber et al., 
2015). We selected BHO as it has been most frequently reported form in the literature to date, 
and we specifically asked users whether they had used this particular product. However it is 
possible that some users were unaware of the extraction technique used; some of our BHO 
sample may have used concentrates that were extracted using alternative methods. Nevertheless, 
our cannabis questions (seven different cannabis products, each depicted by text and image) is 
the most comprehensive we are aware of to date and it excluded alternatives such as traditional 
cannabis oil and dry extract (kief). Finally, we were unable to verify cannabinoid doses in BHO 
and other forms of cannabis. This is an important issue, because higher potency cannabis 
products could potentially reduce respiratory harms if users are able to adjust (titrate) the amount 
they use. There is some evidence for titration with traditional forms of cannabis, although this is 
not of sufficient magnitude to entirely offset the increased dose of THC received when using 
higher potency products (Freeman et al., 2014; van der Pol et al., 2013). 
5 Conclusion 
BHO is a form of refined cannabis product with a very high level of THC, the primary 
psychoactive ingredient in cannabis. This is the largest study of BHO users to date and the first 
to examine BHO user profiles. Although use was reportedly more common among those who 
used it for medical reasons, it was also associated with poorer mental health and greater use of 
other illicit substances. BHO was also reported to produce stronger negative and weaker positive 
effects than traditional high potency cannabis.  
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Table 1. Types of cannabis used by different types of cannabis users. 
  
Non-user (N = 98,003) 
Cannabis user - No 
high potency herbal 
cannabis and BHO use 
(N = 25,371) 
High potency herbal 
cannabis users, no BHO 
use (N = 52,574) BHO users (N = 5,922) 
  N % N % N % N % 
High potency herbal cannabis - - 0 0 52574 100.00 5676 95.85 
Resin/ Hash - - 10278 40.51 32619 62.04 4485 75.73 
Normal weed - - 24129 95.10 45104 85.79 4619 78.00 
Edibles Group - - 4992 19.68 17870 33.99 4321 72.97 
Kief Group - - 1179 4.65 11735 22.32 4005 67.63 
Oil Group - - 692 2.73 4039 7.68 3720 62.82 
Butane hash oil - - 0 0 0 0 5922 100.00 
Table 2. Profiles of different cannabis users (Demographic). 
 
Non-user 
Cannabis user - No high 
potency herbal cannabis and 
BHO use 
High potency herbal cannabis 
users, no BHO use BHO users 
Demographic N % N % N % N % Chi-sq 
Gender 
           Female 41,401 42.96 9,924 39.69 12,880 24.91 1,127 19.49 5567*** 
  Male 54,576 56.63 14.962 59.84 38,582 74.63 4,618 79.85  
  Transgender 398 0.41 117 0.47 238 0.46 38 0.66  
Education 
           Below high school 12978 13.58 3280 13.29 9423 18.51 1467 26.21 4413*** 
  Finish high school 13091 13.70 4644 18.82 10778 21.17 1370 24.48  
  College certificate/ diploma 24454 25.58 6703 27.16 13995 27.49 1207 21.57  
  Undergraduate or above 45060 47.14 10049 40.72 16711 32.83 1553 27.75  
Sexual orientation 
          Bisexual 6458 6.91 2842 11.61 5510 10.90 796 14.18 1287*** 
  Heterosexual 81587 87.29 20099 82.10 42789 84.67 4630 82.49  
  Homosexual 5423 5.80 1540 5.29 2240 4.43 187 3.33  
Daily/ almost daily use (5 or more days a week) of any 
types of cannabis         
  No -  24065 94.85 46881 89.17 4737 79.99 1387*** 
  Yes -  1306 5.15 5693 10.83 1185 20.01  
 
M SD M SD M SD M SD F 
Age 31.30 12.29 27.61 10.75 25.80 8.87 25.68 9.43 3118*** 
***p < .001. 
Table 3. Profiles of different cannabis users (Past 12 months substance use and mental health). 
 
Non-user 
Cannabis user - No high 
potency herbal cannabis and 
BHO use 
High potency herbal 
cannabis users, no BHO 
use BHO users 
Past 12 months substance use N % N % N % N % Chi-sq 
MDMA use 12549 12.80 8308 32.75 24241 46.11 3071 51.86 22286*** 
Cocaine use 9101 9.29 5554 21.89 16001 30.44 2530 42.72 13114*** 
Amphetamine/Methamphetamine use 5570 5.68 3001 11.83 11446 21.77 1416 23.91 9390*** 
Heroin use 416 0.42 173 0.68 594 1.13 228 3.85 972*** 
LSD use 2528 2.58 3158 12.45 10844 20.63 2527 42.67 18937*** 
 M SD M SD M SD M SD F-statistics 
Number of substance use 0.31 0.77 0.80 1.07 1.20 1.24 1.65 1.35 11467*** 
Mental health N % N % N % N % Chi-sq 
Psychosis 688 0.71 170 0.68 541 1.04 57 1.50 83.59*** 
Depression 12539 12.96 3363 13.38 7250 13.96 1158 19.90 237.10*** 
Anxiety 7500 7.75 2183 8.69 4589 8.84 886 15.23 418.32*** 
Obtaining cannabis   N % N % N % Chi-sq 
Purchase   20512 80.85 48249 91.77 5296 89.50 1987*** 
Grow   1747 6.89 5611 10.67 1068 18.05 723*** 
Through prescription   205 0.81 535 1.02 425 7.18 1565*** 
Reason for using cannabis N % N % N % N % Chi-sq 
  Exclusively for recreational use   20588 84.12 37319 72.17 2425 41.67 4730*** 
  Sometimes for medical and mainly for recreational   3033 12.39 12171 23.54 2649 45.48  
  Mainly for medical but sometimes for recreational   690 2.82 2003 3.38 676 11.62  
  Exclusively for medical   164 0.67 220 0.43 72 1.24  
*** p < .001.
Table 4. Multinomial logistic regression (Ref: Cannabis user - No high potency herbal cannabis and BHO use) 
 
Ref: Cannabis user with no high potency cannabis and BHO use   
Ref: High potency herbal cannabis use, 
no BHO use 
 
Non-user 
High potency herbal cannabis 
users – no BHO use BHO users BHO users 
  OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Age 1.02*** (1.02, 1.02) 0.98*** (0.98, 0.99) 0.99*** (0.99, 0.99) 1.01*** (1, 1.01) 
Gender (Ref: Female) 
    
  
    Male 0.80*** (0.77, 0.82) 2.08*** (2.01, 2.15) 3.07*** (2.85, 3.30) 1.48*** (1.38, 1.59) 
  Transgender 0.95 (0.76, 1.18) 1.55*** (1.24, 1.94) 2.14*** (1.44, 3.16) 1.38 (0.96, 1.98) 
Education level (Ref: Below high school) 
  
  
    Finished high school 0.78*** (0.74, 0.82) 0.80*** (0.76, 0.85) 0.66*** (0.60, 0.72) 0.82*** (0.76, 0.89) 
  College certificate/ diploma 0.97 (0.92, 1.02) 0.76*** (0.72, 0.80) 0.43*** (0.40, 0.47) 0.57*** (0.53, 0.62) 
  Undergraduate or above 1.03 (0.98, 1.08) 0.68*** (0.64, 0.71) 0.42*** (0.38, 0.48) 0.62*** (0.57, 0.67) 
Sexual orientation (Ref: Heterosexual) 
  
  
    Bisexual 0.63*** (0.60, 0.66) 0.96 (0.91, 1.01) 1.19*** (1.09, 1.30) 1.22*** (1.14, 1.35) 
  Homosexual 0.96 (0.91, 1.02) 0.61*** (0.57, 0.65) 0.41*** (0.35, 0.47) 0.67*** (0.57, 0.77) 
Number of substance use 0.59*** (0.58, 0.59) 1.30*** (1.28, 1.32) 1.66*** (1.63, 1.70) 1.29*** (1.25, 1.31) 
Psychosis 1.27** (1.06, 1.51) 1.28** (1.07, 1.53) 1.11 (0.85, 1.46) 0.89 (0.69, 1.09) 
Depression 1.00 (0.94, 1.05) 1.18*** (1.11, 1.25) 1.34*** (1.21, 1.48) 1.15** (1.03, 1.25) 
Anxiety 0.92** (0.86, 0.98) 1.05 (0.98, 1.12) 1.80*** (1.60, 2.01) 1.72*** (1.55, 1.91) 
***p < .001; **p < .01.
Running Head: ADOLESCENT IMPULSIVITY AND ALCOHOL USE     1 
Table 5. Effect profiles of BHO and high potency cannabis (only participants who responded to both set of BHO and high potency cannabis 
questions were included). 
 BHO  High potency herbal cannabis   
 M SD M SD t Cohen's D N (Potential N = 5676) 
Urge to use more when stoned 3.91 2.40 4.74 2.53 24.72*** 0.39 4014 
Taste 6.91 2.43 7.88 2.01 22.16*** 0.34 4291 
Overall pleasurable effect 7.79 1.89 8.44 1.51 21.12*** 0.32 4422 
Increase appetite 5.95 2.43 6.64 2.21 21.27*** 0.33 4227 
Ability to talk comfortably 6.64 2.48 7.13 2.24 16.39*** 0.25 4293 
Overall strength 8.49 1.57 8.00 1.43 16.41*** 0.25 4453 
Overall ability to function 6.39 2.42 6.93 2.33 15.35*** 0.24 4226 
Preoccupied/ distracted 4.82 2.48 4.41 2.32 14.48*** 0.23 3939 
Forgetful when stoned 5.28 2.44 4.86 2.32 14.27*** 0.22 4173 
Restless/ Anxious 3.73 2.43 3.22 2.15 12.99*** 0.22 3558 
Purity 7.42 2.38 8.04 2.34 13.48*** 0.21 4075 
Harmful effect on lungs 4.40 2.44 4.80 2.35 10.53*** 0.17 4023 
Worried about talking/looking at you 3.26 2.48 2.95 2.23 10.57*** 0.18 3473 
Relaxed 7.59 2.10 7.94 1.74 10.57*** 0.15 4397 
Sedated/ sleepy 5.61 2.29 5.29 2.16 9.33*** 0.14 4224 
Thought racing 3.67 2.48 3.43 2.39 7.97*** 0.13 3575 
Hangover effect 2.65 2.15 2.42 2.03 7.52*** 0.13 3314 
Overall negative effect 2.95 2.04 2.74 1.95 6.69*** 0.11 3597 
Giggle/laugh 5.74 2.42 5.77 2.49 1.06 0.02 4092 
Sensory experience alteration 5.91 2.44 5.92 2.45 0.36 0.01 4098 
***p < .001.
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